Larvol Delta - GSN000400-A-Study-of-Setanaxib-CoAdministered-With-Pembrolizumab-in-Patients-With-Recurrent-or-Metastatic-Squamous-Cell-Carcinoma-of-Head-and-Neck-SCCHN

setanaxib (GKT831) - Calliditas

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT05323656

Sep 3, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next